Lilly Moves to Update Foundayo Label
Eli Lilly and Company has updated the prescribing information for Foundayo, its widely prescribed GLP-1 receptor agonist, after accumulating patient reports during the critical second week of treatment revealed a pattern of side effects that warranted additional disclosure. The updated label, filed with the FDA on April 4, 2026, adds several adverse reactions and modifies dosing guidance for the initial titration period.
Foundayo, which received FDA approval in late 2025, has rapidly become one of the most prescribed weight-loss medications in the United States, with an estimated 2.3 million active prescriptions. The label update comes as the drug enters its most intensive period of real-world use.
What the Updated Label Includes
The revised prescribing information adds the following adverse reactions to the warnings and precautions section:
- Persistent nausea beyond 72 hours — Previously noted as transient, Lilly now acknowledges that a subset of patients experience prolonged nausea that may require dose adjustment
- Dizziness and lightheadedness — Reported in approximately 8% of patients during Week 2, particularly upon standing
- Vivid dreams and sleep disturbances — A newly identified side effect reported by roughly 5% of patients in post-marketing surveillance
- Transient elevation in liver enzymes — Mild elevations in ALT and AST observed in a small percentage of patients, typically resolving without intervention
- Injection site reactions — Expanded description of localized swelling and induration lasting beyond 48 hours
The Week 2 Phenomenon
Clinicians have noted that the second week of Foundayo treatment appears to represent a critical adjustment period for many patients. During this phase, the drug reaches steady-state plasma concentrations, and the body's GLP-1 signaling pathways undergo significant modulation.
Dr. James Kowalski, an endocrinologist at the Cleveland Clinic, explained that Week 2 side effects are not uncommon with GLP-1 receptor agonists but that Foundayo's specific pharmacokinetic profile may make them more pronounced than with competing drugs.
"The Week 2 window is where we see the most patient calls. Most symptoms resolve by Week 3 or 4, but patients need to be prepared and physicians need to manage expectations proactively." — Dr. James Kowalski, Cleveland Clinic
Patient Reports Drive the Change
The label update was driven primarily by post-marketing surveillance data collected through the FDA's Adverse Event Reporting System (FAERS) and Lilly's own pharmacovigilance program. In the first quarter of 2026, the FAERS database recorded over 12,000 reports related to Foundayo, with approximately 35% describing symptoms during the second week of use.
Social media has also played a role in surfacing patient experiences. Online communities dedicated to GLP-1 drugs have featured extensive discussions about Week 2 symptoms, with many users sharing detailed timelines of their side effects. While anecdotal, these reports helped identify patterns that were subsequently confirmed through formal pharmacovigilance channels.
Lilly's Response and Revised Guidance
In a statement, Eli Lilly emphasized that Foundayo's overall safety profile remains consistent with its clinical trial data and that the label update reflects the company's commitment to transparency. The company has also issued updated guidance for healthcare providers recommending:
- A more gradual titration schedule for patients with BMI below 30
- Proactive counseling about Week 2 symptoms at the time of initial prescription
- Baseline liver function tests before initiating treatment
- Follow-up assessment at the two-week mark to evaluate tolerability
Market and Competitive Implications
The label update arrives at a sensitive time for the GLP-1 drug market. Foundayo competes directly with Novo Nordisk's semaglutide products and Amgen's emerging obesity pipeline. Any perception of safety concerns could shift prescribing patterns, though analysts note that label updates are routine for newly launched medications.
Lilly's stock dipped 1.8% in after-hours trading following the announcement but recovered by the following morning, suggesting that investors view the update as a manageable development rather than a material risk to the drug's commercial trajectory.
What Patients Should Do
Healthcare professionals advise patients currently taking Foundayo not to discontinue the medication without consulting their physician. Those experiencing persistent or severe side effects during Week 2 should contact their prescriber to discuss dose adjustment or supportive care options. The updated label is available on the FDA's drug labeling database and through Lilly's medical information portal.
